Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CNCR |
---|---|---|
09:32 ET | 1023 | 15.9 |
10:30 ET | 100 | 15.91 |
11:02 ET | 100 | 15.815 |
12:16 ET | 470 | 15.7816 |
12:56 ET | 700 | 15.789 |
01:12 ET | 100 | 15.7408 |
01:14 ET | 317 | 15.71 |
03:07 ET | 1600 | 15.7 |
03:39 ET | 100 | 15.83 |
03:45 ET | 200 | 15.72 |
03:54 ET | 100 | 15.87 |
03:57 ET | 318 | 15.82 |
03:59 ET | 0 | 15.86 |
Date | Daily Premium/Discount |
---|---|
02/05/2024 | -0.20% |
02/06/2024 | 0.15% |
02/07/2024 | 0.55% |
02/08/2024 | 0.36% |
02/09/2024 | -0.27% |
02/12/2024 | -0.64% |
02/13/2024 | -0.42% |
02/14/2024 | 0.32% |
02/15/2024 | -0.04% |
02/16/2024 | 0.25% |
02/20/2024 | 0.45% |
02/21/2024 | -0.14% |
02/22/2024 | -0.24% |
02/23/2024 | 0.24% |
02/26/2024 | 0.31% |
02/27/2024 | 0.84% |
02/28/2024 | 0.62% |
02/29/2024 | 0.72% |
03/01/2024 | 0.93% |
03/04/2024 | 0.77% |
03/05/2024 | -0.49% |
03/06/2024 | 0.08% |
03/08/2024 | 0.28% |
03/11/2024 | -0.25% |
03/12/2024 Largest Premium | 1.12% |
03/13/2024 | 0.43% |
03/14/2024 | 0.29% |
03/15/2024 | -0.01% |
03/18/2024 | 0.79% |
03/19/2024 | -0.20% |
03/20/2024 Largest Discount | -0.82% |
03/21/2024 | 0.19% |
03/22/2024 | -0.26% |
03/25/2024 | 0.30% |
03/26/2024 | -0.28% |
03/27/2024 | -0.09% |
03/28/2024 | 0.07% |
04/01/2024 | -0.55% |
04/02/2024 | -0.10% |
04/03/2024 | 0.54% |
04/04/2024 | -0.29% |
04/05/2024 | 0.68% |
04/09/2024 | -0.12% |
04/10/2024 | -0.60% |
04/11/2024 | -0.03% |
04/12/2024 | 0.79% |
04/15/2024 | -0.38% |
04/16/2024 | -0.52% |
04/17/2024 | -0.21% |
04/18/2024 | -0.36% |
04/19/2024 | -0.61% |
04/22/2024 | -0.42% |
04/23/2024 | -0.38% |
04/24/2024 | -0.44% |
04/25/2024 | -0.28% |
04/26/2024 | -0.35% |
04/29/2024 | -0.43% |
04/30/2024 | -0.28% |
05/01/2024 | 0.59% |
05/02/2024 | -0.58% |
US Stock | 86.3% |
---|---|
Non-US Stock | 13.5% |
Cash | 0.2% |
Convertible | 0 |
Non-US Bond | 0 |
Other | 0 |
Healthcare | 99.8% |
---|---|
Basic Mat. | 0 |
Communication Services | 0 |
Consumer Cyclical | 0 |
Consumer Defensive | 0 |
Energy | 0 |
Financial Serv.s | 0 |
Industrials | 0 |
Real Estate | 0 |
Technology | 0 |
Utilities | 0 |
United States | 86.5% |
---|---|
Europe | 6.4% |
Asia/Oceania | 1.5% |
Canada | 0.8% |
Africa | 0 |
Latin America | 0 |
Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
---|---|---|---|---|
Geron Corp | Long | 3.0% | 0.00% | $532.0K |
Acrivon Therapeutics Inc | Long | 2.4% | 0.00% | $424.7K |
ImmunityBio Inc Ordinary Shares | Long | 2.2% | 0.00% | $385.5K |
Cullinan Therapeutics Inc | Long | 2.2% | 0.00% | $378.4K |
Deciphera Pharmaceuticals Inc | Long | 2.2% | 0.00% | $376.3K |
Janux Therapeutics Inc Ordinary Shares | Long | 2.0% | 0.00% | $357.6K |
Enliven Therapeutics Inc | Long | 2.0% | 0.00% | $357.0K |
Nuvation Bio Inc Ordinary Shares - Class A | Long | 1.9% | 0.00% | $323.4K |
Day One Biopharmaceuticals Inc | Long | 1.6% | 0.00% | $285.5K |
Revolution Medicines Inc Ordinary Shares | Long | 1.6% | 0.00% | $276.2K |
The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.
Time Horizon | Star Rating |
---|---|
Overall Rating | 1 out of 5 Stars |
3 Year Rating | 1 out of 5 Stars |
5 Year Rating | 1 out of 5 Stars |
10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | Range Cancer Therapeutics USD |
---|---|
Category | |
Sponsor | Exchange Traded Concepts, LLC |
Inception | October 13, 2015 |
The investment seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index (the “indexâ€). The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRsâ€) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
Total Net Assets | $17.5M |
---|---|
Shares Out. | 1.2M |
Net Asset Value (NAV) | $15.52 |
Prem/Discount to NAV | -0.58% |
P/E Ratio | --- |
Dividend Yield | 0.00% |
Dividend per Share | --- |
Ex-Dividend Date | --- |
Dividend Payment Date | --- |
Beta | --- |
Morningstar Investment Style | Health |
Equity Style | Small Cap Blend |
Credit Quality / Duration | --- |
Actual Management Fee | 0.79% |
---|---|
Actual Mgmt. Expense Ratio (MER) | 0.79% |